Prostate Cancer

>

Latest News

FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

November 21st 2024

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

November 15th 2024

Ready-to-Use 3-Month Leuprolide Depot Formulation Nears FDA Approval
Ready-to-Use 3-Month Leuprolide Depot Formulation Nears FDA Approval

October 30th 2024

Single-Port Surgery Changes the Landscape in Prostate Cancer Treatment
Single-Port Surgery Changes the Landscape in Prostate Cancer Treatment

October 20th 2024

FDA Provides Positive Feedback on AMPLIFY Trial for Prostate Cancer Diagnostic
FDA Provides Positive Feedback on AMPLIFY Trial for Prostate Cancer Diagnostic

October 14th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

<1
...
4546474849